Literature DB >> 24751389

Clinicopathological analysis and survival outcome of duodenal adenocarcinoma.

Myung Jin Kim1, Sae Byeol Choi2, Hyung Joon Han1, Pyoung Jae Park1, Wan Bae Kim1, Tae Jin Song1, Sung Ock Suh1, Sang Yong Choi1.   

Abstract

Duodenal adenocarcinoma is a rare cancer, contributing <10 % of periampullary carcinoma. This study reviews the single center experience of duodenal adenocarcinoma and analyzes the clinical and pathological factors to predict survival and recurrence. The records of 50 patients with duodenal adenocarcinoma who underwent surgical exploration or resection from 1995 to 2010 were reviewed retrospectively. Univariate and multivariate analyses were performed to identify the clinicopathological factors associated with survival and recurrence. There were 35 men and 15 women, with a mean age of 61 years. In multivariate analysis of 50 patients, R0 resection [p = 0.041, hazard ratio (HR) = 3.569, 95% confidence interval (CI) = 1.057-12.054] and symptom at initial admission (p = 0.025, HR = 11.210, 95% CI = 1.354-92.812) were independent prognostic factors for overall survival. Thirty-six patients underwent curative resection (resectability 72%). The 5-year survival rates for curative and noncurative resections were 46.4% and 0%, respectively. Univariate analysis of 36 patients who underwent R0 resection revealed that symptoms at initial admission (p = 0.023), presence of lymph node metastasis (p = 0.034), and perineural invasion (p = 0.025) were significant prognostic factors after curative resection. There was no significant factor for overall survival in the multivariate analysis. There was recurrence in 15 patients, mainly as liver metastasis. Multivariate analysis revealed that presence of symptom (p = 0.047, HR = 5.362, 95% CI = 1.021-28.149) and ulcerative tumor (p = 0.036, HR = 5.668, 95% CI = 1.123-28.619) were independent factors for disease free survival. An aggressive surgical approach to achieve R0 resection was important to enhance survival. Most of the recurrence occurred within 1 year after surgery. Close follow-up is necessary after surgical resection.
Copyright © 2014. Published by Elsevier B.V.

Entities:  

Keywords:  Duodenal cancer; Lymph node metastasis; Pancreaticoduodenectomy; R0 resection

Mesh:

Year:  2014        PMID: 24751389     DOI: 10.1016/j.kjms.2013.12.006

Source DB:  PubMed          Journal:  Kaohsiung J Med Sci        ISSN: 1607-551X            Impact factor:   2.744


  12 in total

Review 1.  Limited resection vs. pancreaticoduodenectomy for primary duodenal adenocarcinoma: a systematic review and meta-analysis.

Authors:  Pipit Burasakarn; Ryota Higuchi; Souya Nunobe; Shingo Kanaji; Hidetoshi Eguchi; Ken-Ichi Okada; Tsutomu Fujii; Yuichi Nagakawa; Kengo Kanetaka; Hiroharu Yamashita; Suguru Yamada; Shinji Kuroda; Toru Aoyama; Takahiro Akahori; Kenji Nakagawa; Masakazu Yamamoto; Hiroki Yamaue; Masayuki Sho; Yasuhiro Kodera
Journal:  Int J Clin Oncol       Date:  2021-01-01       Impact factor: 3.402

2.  Symptoms at diagnosis as independent prognostic factors in retroperitoneal liposarcoma.

Authors:  Satoru Taguchi; Haruki Kume; Hiroshi Fukuhara; Teppei Morikawa; Shigenori Kakutani; Yuta Takeshima; Hideyo Miyazaki; Motofumi Suzuki; Tetsuya Fujimura; Tohru Nakagawa; Akira Ishikawa; Yasuhiko Igawa; Yukio Homma
Journal:  Mol Clin Oncol       Date:  2015-12-08

3.  Duodenal adenocarcinoma successfully diagnosed with transabdominal ultrasonography.

Authors:  Hirokazu Yamazaki; Takanori Sakaguchi; Hatsuko Nasu; Katsutoshi Miura; Yasushi Shibasaki; Hajime Yuasa
Journal:  J Med Ultrason (2001)       Date:  2017-04-24       Impact factor: 1.314

4.  Widespread lymph node recurrence of major duodenal papilla cancer following pancreaticoduodenectomy.

Authors:  Bai-Sen Li; Hui Shi; Min Wen; Ming-Yong Xiao; Jian Wang
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

5.  Adenocarcinoma of the third and fourth portions of the duodenum: The capsule endoscopy value.

Authors:  Feliciano Chanana Paquissi; Ana Henriqueta Filipe Bunga Pimentel Lima; Maria de Fátima do Nascimento Vieira Lopes; Francisco Viamontes Diaz
Journal:  World J Gastroenterol       Date:  2015-08-21       Impact factor: 5.742

6.  Wilkie's Syndrome and Left Adnexal Mass: Unusual Presentation of Duodenal Adenocarcinoma.

Authors:  Clement Wilfred Devadass; Geetha V Patil Okaly; Sudha Hm; Sreekar Agumbe Pai; H Sridher
Journal:  J Clin Diagn Res       Date:  2014-08-20

7.  Neoadjuvant chemotherapy in locally advanced duodenal adenocarcinoma.

Authors:  Carlos Velandia; Rafael Delgado Morales; Carlos Coello; Armando Gil Mendoza; Gabriel Pérez; Emperatriz Aguero
Journal:  Ecancermedicalscience       Date:  2018-03-05

8.  Outcomes and Treatment Options for Duodenal Adenocarcinoma: A Systematic Review and Meta-Analysis.

Authors:  Laura L Meijer; Anna J Alberga; Jacob K de Bakker; Hans J van der Vliet; Tessa Y S Le Large; Nicole C T van Grieken; Ralph de Vries; Freek Daams; Barbara M Zonderhuis; Geert Kazemier
Journal:  Ann Surg Oncol       Date:  2018-06-26       Impact factor: 5.344

9.  Immune infiltrating cells in duodenal cancers.

Authors:  G Donisi; G Capretti; N Cortese; A Rigamonti; F Gavazzi; G Nappo; A Pulvirenti; M Sollai; P Spaggiari; A Zerbi; F Marchesi
Journal:  J Transl Med       Date:  2020-09-03       Impact factor: 5.531

10.  Tumour stage and resection margin status are independent survival factors following partial pancreatoduodenectomy for duodenal adenocarcinoma.

Authors:  Kulbir Mann; T Gilbert; S Cicconi; R Jackson; P Whelan; F Campbell; C Halloran; J Neoptolemos; P Ghaneh
Journal:  Langenbecks Arch Surg       Date:  2019-04-10       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.